ASIA unversity:Item 310904400/86933
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 90429/105609 (86%)
造访人次 : 10534901      在线人数 : 319
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    题名: Signaling cross-talk in the resistance to HER family receptor targeted therapy.
    作者: Yamaguchi, H;Yamaguchi, H.;Chang, S-S.;Chang, S-S.;Hsu, J.L.;Hsu, J.L.;洪明奇*
    贡献者: 生物科技學系
    日期: 2014
    上传时间: 2014-11-07 14:53:06 (UTC+8)
    摘要: Epidermal growth factor receptor (EGFR) and human EGFR 2 (HER2) have an important role in the initiation and progression of various types of cancer. Inhibitors targeting these receptor tyrosine kinases are some of the most successful targeted anticancer drugs widely used for cancer treatment; however, cancer cells have mechanisms of intrinsic and acquired drug resistance that pose as major obstacles in drug efficacy. Extensive studies from both clinical and laboratory research have identified several molecular mechanisms underlying resistance. Among them is the role of signaling cross-talk between the EGFR/HER2 and other signaling pathways. In this review, we focus particularly on this signaling cross-talk at the receptor, mediator and effector levels, and further discuss alternative approaches to overcome resistance. In addition to well-recognized signaling cross-talk involved in the resistance, we also introduce the cross-talk between EGFR/HER2-mediated pathways and pathways triggered by other types of receptors, including those of the Notch, Wnt and TNFR/IKK/NF-κB pathways, and discuss the potential role of targeting this cross-talk to sensitize cells to EGFR/HER2 inhibitors.
    關聯: ONCOGENE;33(9):1073-81.
    显示于类别:[生物科技學系] 期刊論文


    档案 大小格式浏览次数


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈